(Reuters) – Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.
A separate Sanofi-led trial outside of the United States in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing, the companies said.
The trial results come after a study in April showed that Kevzara may only help the sickest coronavirus patients.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Aditya Soni)
